Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Pure Bioscience (PURE)

Pure Bioscience (PURE)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0653 +0.0053 (+8.83%) 04/25/25 [OTC US]
N/A x N/A N/A x N/A
Post-market 0.0653 unch (unch) 12:49 ET
Profile for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Pure Bioscience 771 JAMACHA ROAD #512 EL CAJON CA 92019 USA

www.purebio.com Employees: 12 P: 619-596-8600

Sector:

Medical

INDUSTRY GROUPING:

Medical Products

Description:

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.

Key Statistics

Overview:

Market Capitalization, $K 6,711
Enterprise Value, $K 9,241
Shares Outstanding, K 111,856
Annual Sales, $ 1,960 K
Annual Net Income, $ -3,350 K
Last Quarter Sales, $ 390 K
Last Quarter Net Income, $ -800 K
EBIT, $ -2,820 K
EBITDA, $ -2,670 K
60-Month Beta 0.27
% of Insider Shareholders 43.54%
% of Institutional Shareholders 0.00%
Float, K 63,154
% Float 56.46%
Short Volume Ratio 0.99

Growth:

1-Year Return -6.71%
3-Year Return -62.64%
5-Year Return -89.30%
5-Year Revenue Growth 2.62%
5-Year Earnings Growth 66.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.01 on 03/17/25
Next Earnings Date 06/13/25
Earnings Per Share ttm -0.04
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-8 on 08/15/12

PURE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -383.19%
Profit Margin % -170.92%
Debt/Equity -0.93
Price/Sales 3.70
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.04
Interest Coverage -19.94
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective